SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI8/29/2006 1:37:30 PM
  Read Replies (1) of 1321
 
1:03 (Dow Jones) QLT (QLTI) shares get a boost from a Globe and Mail newspaper report saying a major shareholder, backed by a private equity firm, offered to take the company private in February. But QLTI, maker of anti-blindness drug Visudyne, "politely" turned the offer down, embarking on a $104M share buyback instead. BMO Capital expresses skepticism, saying there's doubt buyers will step up until a patent-infringement suit launched by Tap Pharmaceuticals is resolved, as well as the full effect of the launch of a competing drug - Lucentis - is known. QLTI up 3.8% at $7.88. (AMG)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News